Surging sales 01 Johnson & Johnson's prescription nteellt'lnes and the rebound of its recall-plagued consumer health business lifted -quarter profit 190/0. 'l Ite health-care giant also enjoyed a $707 million tax benefit from writing off money-losing subsidiary Scios. The maker of baby shampoo and bio- logical thugs said on Tuesday that fourth- quarter net income was $3.52 billion, or $1.23 per share, up from $2.57 billion, or 91 cents per share, a year earlier. Excluding one-time items, income was $1.24 per share. Analysts expected four cents less. Revenue tbtalled $18.36 billion, up 4.5%. Analysts expected $17.94 billion, according to FactSet Research Systems Inc. "Each of Johnson & Johnson's three main business units reported better sales than investors were expecting despite